Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2021) Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Metadata

Item Type: Conference or Workshop Item
Authors/Creators:
Dates:
  • Published: September 2021
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Aug 2022 11:49
Last Modified: 05 Aug 2022 11:49
Status: Published
Identification Number: 10.1002/art.41966
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)